Sana Biotechnology annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Sana Biotechnology R&D Spending Growth & History (SANA)
Sana Biotechnology's r&d spending was $132.0M for fiscal 2025.
View full Sana Biotechnology company overviewSana Biotechnology annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $132.0M | −$83.7M | −38.81% |
| 2024 | 2024-12-31 | $215.7M | −$46.1M | −17.62% |
| 2023 | 2023-12-31 | $261.8M | −$24.1M | −8.42% |
| 2022 | 2022-12-31 | $285.9M | $37.3M | +14.99% |
| 2021 | 2021-12-31 | $248.6M | $115.7M | +87.02% |
| 2020 | 2020-12-31 | $132.9M | $33.4M | +33.49% |
| 2019 | 2019-12-31 | $99.6M | — | — |
Sana Biotechnology quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $30.7M | $968,000 | +3.25% |
| Q1 2026 | 2026-03-31 | $28.7M | −$8.5M | −22.78% |
| Q4 2025 | 2025-12-31 | $34.9M | −$10.2M | −22.64% |
| Q3 2025 | 2025-09-30 | $30.1M | −$23.1M | −43.42% |
| Q2 2025 | 2025-06-30 | $29.8M | −$31.1M | −51.11% |
| Q1 2025 | 2025-03-31 | $37.2M | −$19.3M | −34.12% |
| Q4 2024 | 2024-12-31 | $45.1M | −$10.8M | −19.36% |
| Q3 2024 | 2024-09-30 | $53.2M | −$12.4M | −18.91% |
| Q2 2024 | 2024-06-30 | $60.9M | −$12.2M | −16.66% |
| Q1 2024 | 2024-03-31 | $56.4M | −$10.7M | −15.96% |
| Q4 2023 | 2023-12-31 | $56.0M | −$7.9M | −12.41% |
| Q3 2023 | 2023-09-30 | $65.6M | −$11.1M | −14.49% |
| Q2 2023 | 2023-06-30 | $73.0M | $504,000 | +0.69% |
| Q1 2023 | 2023-03-31 | $67.2M | −$5.5M | −7.60% |
| Q4 2022 | 2022-12-31 | $63.9M | −$44.6M | −41.09% |
| Q3 2022 | 2022-09-30 | $76.7M | $23.5M | +44.12% |
| Q2 2022 | 2022-06-30 | $72.5M | $27.5M | +61.21% |
| Q1 2022 | 2022-03-31 | $72.7M | $30.8M | +73.56% |
| Q4 2021 | 2021-12-31 | $108.5M | $72.9M | +204.99% |
| Q3 2021 | 2021-09-30 | $53.2M | $13.2M | +32.93% |
| Q2 2021 | 2021-06-30 | $45.0M | $15.0M | +50.03% |
| Q1 2021 | 2021-03-31 | $41.9M | $14.6M | +53.29% |
| Q4 2020 | 2020-12-31 | $35.6M | — | — |
| Q3 2020 | 2020-09-30 | $40.1M | — | — |
| Q2 2020 | 2020-06-30 | $30.0M | — | — |
| Q1 2020 | 2020-03-31 | $27.3M | — | — |
Sana Biotechnology r&d spending trends
Over the last five fiscal years, Sana Biotechnology's r&d spending decreased from $132.9M to $132.0M, a change of −$964,000. The latest reported quarter, Q2 2026, shows $30.7M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sana Biotechnology source filings ↗